Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Stopped Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns

Conditions

• Pancreatic Ductal Adenocarcinoma
• Colorectal Cancer
• Gastric Cancer
• Squamous Cell Carcinoma of the Head and Neck
• Bone Cancer
• Advanced Cancer
• Recurrent Disease
• Metastatic Tumours

Interventions

• DRUG: 177Lu-3BP-227 (also called 177Lu-IPN01087)

Sponsor

Ipsen